MAMariette T. Ackermans

Mariette T. Ackermans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariette T. Ackermans has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enzymatic digestion of hair increases extraction yields of cortisol: a novel two-dimensional liquid chromatography-tandem mass spectrometry method for hair cortisol analysis

    by Dewi van Harskamp, Mariëtte T. Ackermans, Wjera V. Wickenhagen, Annemieke C. Heijboer, Johannes B. van Goudoever

    Hair cortisol concentration is a retrospective, long-term measure of cortisol secretion, often used as a biomarker for chronic stress or suspected cyclic Cushing’s syndrome. Various methods for hair cortisol extraction, typically involving intact, minced, or milled hair incubated with methanol or extraction buffers, may not achieve complete extraction. Incomplete extraction can bias results, particularly when comparing hair samples of differing thickness and texture. Additionally, sample-to-sample variation might be caused by inconsistent cutting or grinding of the hair by different technicians. We aimed to achieve complete cortisol extraction through the enzymatic digestion of hair. After digestion and sample clean-up, we analyzed the final extracts using two-dimensional liquid chromatography-mass spectrometry. Complete digestion was observed with an overnight enzymatic reaction. This method demonstrated high reproducibility, with an intra-day precision of 3.6%, and inter-day precision of 6.5% in a homogenized pool. Moreover, duplicate CV% of intact hairlocks ranged from 0.1% to 8.9%. Our protocol does not influence the cortisol concentration. It is less labor-intensive and more consistent than mincing or milling hair. Our extraction yield was higher compared to the commonly used methanol extraction method. Samples extracted with methanol showed, on average, 19% lower cortisol concentrations than those measured in digested aliquots. We have developed and validated a new, superior method for extracting cortisol from hair utilizing enzymatic digestion. This strategy provides a more thorough extraction, greater consistency, and requires less labor than traditional methods. Graphical Abstract


  • Open Access

    Explaining unexplained hypoglycemia: How LC-MS/MS can help

    by M.T. Ackermans, J. Hopman, A.C. Heijboer, S.E. Siegelaar


  • Open Access

    Hematocrit and standardization in DBS analysis: A practical approach for hormones mainly present in the plasma fraction

    by Mariëtte T. Ackermans, Vera de Kleijne, Frans Martens, Annemieke C. Heijboer


  • Solutions for Hematocrit Bias in Dried Blood Spot Hormone Analysis

    by Vera de Kleijne, Isabelle Kohler, Annemieke Cheijboer, Mariëtte T Ackermans

    Over the last years, dried blood spot (DBS) sampling has gained significant interest due to development of analytical techniques combined with DBS, the simplicity and low cost of the method. Despit...


  • Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study

    by Kevin Stroek, An Ruiter, Annelieke van der Linde, Mariette Ackermans, Marelle J Bouva, Henk Engel, Bernadette Jakobs, Evelien A Kemper, Erica L T van Den Akker, Mirjam E van Albada, et al.

    Context: Newborn screening (NBS) for classic congenital adrenal hyperplasia (CAH) consists of 17-hydroxyprogesterone (17-OHP) measurement with gestational age–adjusted cutoffs. A second heel puncture (HP) is performed in newborns with inconclusive results to reduce false positives. Objective: We assessed the accuracy and turnaround time of the current CAH NBS algorithm in comparison with alternative algorithms by performing a second-tier 21-deoxycortisol (21-DF) pilot study. Methods: Dried blood spots (DBS) of newborns with inconclusive and positive 17-OHP (immunoassay) first HP results were sent from regional NBS laboratories to the Amsterdam UMC Endocrine Laboratory. In 2017-2019, 21-DF concentrations were analyzed by LC-MS/MS in parallel with routine NBS. Diagnoses were confirmed by mutation analysis. Results: A total of 328 DBS were analyzed; 37 newborns had confirmed classic CAH, 33 were false-positive and 258 were categorized as negative in the second HP following the current algorithm. With second-tier testing, all 37 confirmed CAH had elevated 21-DF, while all 33 false positives and 253/258 second-HP negatives had undetectable 21-DF. The elevated 21-DF of the other 5 newborns may be NBS false negatives or second-tier false positives. Adding the second-tier results to inconclusive first HPs reduced the number of false positives to 11 and prevented all 286 second HPs. Adding the second tier to both positive and inconclusive first HPs eliminated all false positives but delayed referral for 31 CAH patients (1-4 days). Conclusion: Application of the second-tier 21-DF measurement to inconclusive first HPs improved our CAH NBS by reducing false positives, abolishing the second HP, and thereby shortening referral time.


  • Open Access

    Metabolite Profile of Treatment-Naive Metabolic Syndrome Subjects in Relation to Cardiovascular Disease Risk

    by Moritz V. Warmbrunn, Annefleur M. Koopen, Nicolien C. de Clercq, Pieter F. de Groot, Ruud S. Kootte, Kristien E. C. Bouter, Kasper W. ter Horst, Annick V. Hartstra, Mireille J. Serlie, Mariette T. Ackermans, et al.

    Metabolic syndrome (MetSyn) is an important risk factor for type 2 diabetes and cardiovascular diseases (CVD). This study aimed to find distinct plasma metabolite profiles between insulin-resistant and non-insulin resistant subjects with MetSyn and evaluate if MetSyn metabolite profiles are related to CVD risk and lipid fluxes. In a cross-sectional study, untargeted metabolomics of treatment-naive males with MetSyn (n = 132) were analyzed together with clinical parameters. In a subset of MetSyn participants, CVD risk was calculated using the Framingham score (n = 111), and lipolysis (n = 39) was measured by a two-step hyperinsulinemic euglycemic clamp using [1,1,2,3,3-2H5] glycerol to calculate lipolysis suppression rates. Peripheral insulin resistance was related to fatty acid metabolism and glycerolphosphorylcholine. Interestingly, although insulin resistance is considered to be a risk factor for CVD, we observed that there was little correspondence between metabolites associated with insulin resistance and metabolites associated with CVD risk. The latter mainly belonged to the androgenic steroid, fatty acid, phosphatidylethanolamine, and phophatidylcholine pathways. These data provide new insights into metabolic changes in mild MetSyn pathophysiology and MetSyn CVD risk related to lipid metabolism. Prospective studies may focus on the pathophysiological role of the here-identified biomarkers.


  • Striatal dopamine regulates systemic glucose metabolism in humans and mice

    by Kasper W. ter Horst, Nicolette M. Lammers, Richard Trinko, Darren M. Opland, Martijn Figee, Mariette T. Ackermans, Jan Booij, Pepijn van Den Munckhof, P. Richard Schuurman, Eric Fliers, et al.

    The brain is emerging as an important regulator of systemic glucose metabolism. Accumulating data from animal and observational human studies suggest that striatal dopamine signaling plays a role in glucose regulation, but direct evidence in humans is currently lacking. We present a series of experiments supporting the regulation of peripheral glucose metabolism by striatal dopamine signaling. First, we present the case of a diabetes patient who displayed strongly reduced insulin requirements after treatment with bilateral deep brain stimulation (DBS) targeting the anterior limb of the internal capsule. Next, we show that DBS in this striatal area, which induced dopamine release, increased hepatic and peripheral insulin sensitivity in 14 nondiabetic patients with obsessive-compulsive disorder. Conversely, systemic dopamine depletion reduced peripheral insulin sensitivity in healthy subjects. Supporting these human data, we demonstrate that optogenetic activation of dopamine D1 receptor–expressing neurons in the nucleus accumbens increased glucose tolerance and insulin sensitivity in mice. Together, these findings support the hypothesis that striatal neuronal activity regulates systemic glucose metabolism.